Liu Yunyi, Li Juan, Ou Hailong, Qi Dan, Hu Bei, Xu Yuxi, Hu Jian, Xiong Yi, Xia Luling, Huang Jason H, Hu Xiaoxiao, Wu Erxi
State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Biology, Molecular Science and Biomedicine Laboratory and Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan 410082, China.
Department of Neurosurgery and Neuroscience Institute, Baylor Scott & White Health, Temple, TX 76508, USA.
Genes Dis. 2022 Aug 3;10(5):2137-2150. doi: 10.1016/j.gendis.2022.07.002. eCollection 2023 Sep.
Aptamers, short single DNA or RNA oligonucleotides, have shown immense application potential as molecular probes for the early diagnosis and therapy of cancer. However, conventional cell-SELEX technologies for aptamer discovery are time-consuming and laborious. Here we discovered a new aptamer BC-3 by using an improved rapid X-Aptamer selection process for human bladder carcinoma, for which there is no specific molecular probe yet. We show that BC-3 exhibited excellent affinity in bladder cancer cells but not normal cells. We demonstrate that BC-3 displayed high selectivity for tumor cells over their normal counterparts , in mice, and in patient tumor tissue specimens. Further endocytosis pathway analysis revealed that BC-3 internalized into bladder cancer cells via clathrin-mediated endocytosis. Importantly, we identified ribosomal protein S7 (RPS7) as the binding target of BC-3 via an integrated methodology (mass spectrometry, colocalization assay, and immunoblotting). Together, we report that a novel aptamer BC-3 is discovered for bladder cancer and its properties in the disease are unearthed. Our findings will facilitate the discovery of novel diagnostic and therapeutic strategies for bladder cancer.
适体是短的单链DNA或RNA寡核苷酸,作为癌症早期诊断和治疗的分子探针显示出巨大的应用潜力。然而,用于发现适体的传统细胞SELEX技术既耗时又费力。在这里,我们通过使用改进的快速X-适体筛选方法针对人膀胱癌发现了一种新的适体BC-3,目前尚无针对该癌症的特异性分子探针。我们表明,BC-3在膀胱癌细胞中表现出优异的亲和力,但在正常细胞中则不然。我们证明,在小鼠和患者肿瘤组织标本中,BC-3对肿瘤细胞显示出比对正常细胞更高的选择性。进一步的内吞途径分析表明,BC-3通过网格蛋白介导的内吞作用内化到膀胱癌细胞中。重要的是,我们通过一种综合方法(质谱分析、共定位分析和免疫印迹)确定核糖体蛋白S7(RPS7)为BC-3的结合靶点。我们共同报告,发现了一种针对膀胱癌的新型适体BC-3,并揭示了其在该疾病中的特性。我们的发现将有助于发现针对膀胱癌的新型诊断和治疗策略。
Acc Chem Res. 2016-8-15
PLoS One. 2013-12-20
Aging Dis. 2023-11-26
Bioact Mater. 2021-10-15
Signal Transduct Target Ther. 2021-8-30
Cell Death Dis. 2021-5-2
Science. 2020-9-4
Protein Sci. 2021-1
Nucleic Acids Res. 2020-7-27